After the third dose of the COVID-19 vaccine, the immune response in healthy volunteers who received 2 doses of COVID19 vaccine (CoronaVac or ChAdOx1) at least three months. COVID-19 vaccine, Third dose, ChAdOx1, coronavac, Sinovac, BNT162b2, Sinopharm
Conditions
Interventions
Administration of 0.5 ml of BBIBP-CorV intramuscular for 1 dose,Administration of 0.5 ml of AZD1222 intramuscular for 1 dose,Administration of 0.5 ml of BNT162b2 intramuscular for 1 dose,Administratio
CoronaVac/BBIBP-CorV,CoronaVac/AZD1222,CoronaVac/BNT162b2,AZD1222/BBIBP-CorV,AZD1222/BNT162b2,AZD1222/AZD1222
Sponsors
Chulabhorn Royal Academy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. 18 years old or more 2. No history of a severe allergic reaction to the prior vaccine. 3. No fever nor history of fever within 14 days. 4. No symptoms of respiratory tract infection within 14 days. 5. Received two doses of COVID-19 vaccine for at least 3 months 6. sign informed consent to the study.
Exclusion criteria
Exclusion criteria: 1. pregnancy. 2. lactation. 3. History of SARS-CoV-2 infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Humoral immunity 4 weeks after third dose 4 weeks after the third dose of the vaccine Double antigen technique for detection of Antibody level of total antibody of spike protein of SARS-CoV-2 | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety profile after vaccination in each intervention arms 4 weeks after the third dose of the vaccine Solicited and non-solicited adverse events,Humoral immunity 4 weeks after third dose 4 weeks after the third dose of the vaccine Surrogate Neutralizing antibody | — |
Countries
Thailand
Contacts
Public ContactKriangkrai Tawinprai
HRH Princess Chulabhorn College of Medical Science
Outcome results
None listed